Contrive Datum Insights has published "Veterinary Oncology Market Size, Share & Industry Analysis, By Therapy modality (Surgical Oncology, Chemotherapy, Radiation Therapy, Targeted Small-Molecule Therapy, Immunotherapy, Other Therapies), Cancer indication (Lymphoma, Mast Cell Tumor, Osteosarcoma, Melanoma, Soft Tissue Sarcoma, Mammary Gland Tumors, Hemangiosarcoma, Carcinomas, Other Cancer Types), Tumor classification (Solid Tumors (Localized), Hematologic/Lymphoid Tumors, Metastatic/Disseminated Disease), Animal type (Dogs (Canine), Cats (Feline), Horses (Equine)), Route of administration (Intravenous, Oral, Subcutaneous, Intralesional/Intratumoral, Inhaled/Intranasal, Topical), Treatment setting / end user (Veterinary Referral & Oncology Specialty Centers, General Practice / Primary Care Veterinary Clinics, Academic Veterinary Teaching Hospitals, Corporate Multi-Site Veterinary Hospital Groups), Development / regulatory stage (Approved / Fully Licensed Products, Conditionally Licensed Products, Investigational / Pipeline Products), Diagnostic & monitoring modality (Histopathology & Cytology, Diagnostic Imaging, Liquid Biopsy / Early Cancer Detection Tests, Genomic/Molecular Tumor Profiling, Drug Sensitivity / Companion Diagnostics), Treatment intent / care pathway stage (Curative-Intent Treatment, Adjuvant/Neoadjuvant Therapy, Palliative/Supportive Care, Post-Remission Maintenance & Surveillance), Distribution channel (Veterinary Hospitals & Clinics (Direct), Veterinary Distributors/Wholesalers, Diagnostic Reference Laboratories, Online/E-commerce Veterinary Pharmacies), and Regional Forecast, 2026-2034". The study sizes the global veterinary oncology market at USD 1820 million in 2025 and projects growth from USD 2040 million in 2026 to USD 5100 million by 2034, a compound annual growth rate of 12.14% across the forecast period.
Veterinary oncology covers the diagnosis, staging and treatment of cancer in companion and performance animals, spanning surgical removal of tumors, injectable and oral chemotherapy protocols, external-beam radiation therapy, newer targeted small-molecule and immunotherapy agents, and the diagnostic tools used to detect and monitor disease, including histopathology, diagnostic imaging, liquid biopsy and molecular tumor profiling. Buyers are veterinary referral and specialty oncology centers, general practice clinics that refer complex cases onward, academic teaching hospitals, and the corporate multi-site hospital groups that increasingly build oncology service lines across their networks. Treatment decisions are shaped by the animal's tumor type and stage, the owner's willingness and ability to pay for advanced care, and whether the intent is curative, palliative or long-term surveillance.
Rising Companion-Animal Cancer Diagnosis Rates
Rising Companion-Animal Cancer Diagnosis Rates is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 12.14% a year, the therapy modality lines exposed to it move fastest: Immunotherapy compounds at 20.65%, taking its share of revenue from 7% to 14% and its value from USD 127 million to USD 714 million.
A more favourable outcome is possible. If bull assumes faster-than-expected conversion of pipeline targeted and immunotherapy products from conditional to full licensing, sustained corporate multi-site hospital network expansion, and continued pet insurance penetration growth in North America and Europe, 2034 revenue reaches USD 5870 million instead of the USD 5100 million the base case carries.
On the downside, bear assumes slower specialist workforce growth constrains referral-center capacity, cost sensitivity reduces owner uptake of advanced modalities during any broader economic slowdown, and conditional licenses take longer than expected to convert to full approval, which would hold 2034 revenue to USD 4340 million. Chemotherapy, which carries 32% of 2025 revenue, already grows at only 8.55% against the market's 12.14%, so the largest part of the base is also its slowest.
Chemotherapy Scale Against Immunotherapy Momentum
The therapy modality axis, not the regional one, is what divides the field. Chemotherapy is the volume position, 32% of 2025 revenue at USD 582 million, holding 24% through 2034, and it is defended by scale. Immunotherapy is the growth position at 20.65%, and it is open. Strength in one does not carry into the other.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Therapy modality | Chemotherapy | 32% · USD 582 million | — |
| Cancer indication | Lymphoma | 24% · USD 437 million | Hemangiosarcoma 16.4% |
| Tumor classification | Solid Tumors (Localized) | 55% · USD 1001 million | Metastatic/Disseminated Disease 16.4% |
| Animal type | Dogs (Canine) | 78% · USD 1420 million | Cats (Feline) 14.05% |
| Route of administration | Intravenous | 42% · USD 764 million | Oral 13.71% |
| Treatment setting / end user | Veterinary Referral & Oncology Specialty Centers | 40% · USD 728 million | Corporate Multi-Site Veterinary Hospital Groups 16.79% |
| Development / regulatory stage | Approved / Fully Licensed Products | 72% · USD 1310 million | Investigational / Pipeline Products 15.44% |
| Diagnostic & monitoring modality | Histopathology & Cytology | 45% · USD 819 million | Liquid Biopsy / Early Cancer Detection Tests 17.89% |
| Treatment intent / care pathway stage | Curative-Intent Treatment | 38% · USD 692 million | Post-Remission Maintenance & Surveillance 16.58% |
| Distribution channel | Veterinary Hospitals & Clinics (Direct) | 58% · USD 1056 million | Online/E-commerce Veterinary Pharmacies 24.11% |
- Based on regional analysis, North America led the global veterinary oncology market in 2025 with 45% of global revenue at USD 819 million, reaching USD 2142 million by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 16% in 2025 to 21% in 2034, with revenue growing from USD 291 million to USD 1071 million.
- Middle East and Africa remains the smallest region throughout, at 5% of 2025 revenue and 4.5% by 2034.
- No therapy modality line grows faster than Immunotherapy, at a projected 20.65%.
- The United States is the largest single country market at USD 672 million in 2025, 36.92% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across ten axes: by therapy modality, and by cancer indication, tumor classification, animal type, route of administration, treatment setting / end user, development / regulatory stage, diagnostic & monitoring modality, treatment intent / care pathway stage and distribution channel. The headline total carries bear, base and bull cases at USD 4340 million and USD 5870 million by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.